These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

556 related items for PubMed ID: 19728747

  • 21. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.
    Budde K, Becker T, Arns W, Sommerer C, Reinke P, Eisenberger U, Kramer S, Fischer W, Gschaidmeier H, Pietruck F, ZEUS Study Investigators.
    Lancet; 2011 Mar 05; 377(9768):837-47. PubMed ID: 21334736
    [Abstract] [Full Text] [Related]

  • 22. Clinical pharmacokinetics and pharmacodynamics of prednisolone and prednisone in solid organ transplantation.
    Bergmann TK, Barraclough KA, Lee KJ, Staatz CE.
    Clin Pharmacokinet; 2012 Nov 05; 51(11):711-41. PubMed ID: 23018468
    [Abstract] [Full Text] [Related]

  • 23. A comparison of the effect of ciclosporin and sirolimus on the pharmokinetics of mycophenolate in renal transplant patients.
    Picard N, Prémaud A, Rousseau A, Le Meur Y, Marquet P.
    Br J Clin Pharmacol; 2006 Oct 05; 62(4):477-84. PubMed ID: 16995869
    [Abstract] [Full Text] [Related]

  • 24. Pharmacokinetic interaction between levofloxacin and ciclosporin or tacrolimus in kidney transplant recipients: ciclosporin, tacrolimus and levofloxacin in renal transplantation.
    Federico S, Carrano R, Capone D, Gentile A, Palmiero G, Basile V.
    Clin Pharmacokinet; 2006 Oct 05; 45(2):169-75. PubMed ID: 16485913
    [Abstract] [Full Text] [Related]

  • 25. Benefit-risk assessment of sirolimus in renal transplantation.
    Kuypers DR.
    Drug Saf; 2005 Oct 05; 28(2):153-81. PubMed ID: 15691225
    [Abstract] [Full Text] [Related]

  • 26. Corticosteroid interactions with cyclosporine, tacrolimus, mycophenolate, and sirolimus: fact or fiction?
    Lam S, Partovi N, Ting LS, Ensom MH.
    Ann Pharmacother; 2008 Jul 05; 42(7):1037-47. PubMed ID: 18594053
    [Abstract] [Full Text] [Related]

  • 27. Treatment strategies to minimize or prevent chronic allograft dysfunction in pediatric renal transplant recipients: an overview.
    Höcker B, Tönshoff B.
    Paediatr Drugs; 2009 Jul 05; 11(6):381-96. PubMed ID: 19877724
    [Abstract] [Full Text] [Related]

  • 28. Calcineurin inhibitor sparing in paediatric solid organ transplantation : managing the efficacy/toxicity conundrum.
    Tredger JM, Brown NW, Dhawan A.
    Drugs; 2008 Jul 05; 68(10):1385-414. PubMed ID: 18578558
    [Abstract] [Full Text] [Related]

  • 29. Risk Assessment of Drug-Drug Interactions of Calcineurin Inhibitors Affecting Sirolimus Pharmacokinetics in Renal Transplant Patients.
    Emoto C, Vinks AA, Fukuda T.
    Ther Drug Monit; 2016 Oct 05; 38(5):607-13. PubMed ID: 27310200
    [Abstract] [Full Text] [Related]

  • 30. Safety and efficacy of TOR inhibitors in pediatric renal transplant recipients.
    Ettenger RB, Grimm EM.
    Am J Kidney Dis; 2001 Oct 05; 38(4 Suppl 2):S22-8. PubMed ID: 11583941
    [Abstract] [Full Text] [Related]

  • 31. Effect of fluconazole on the pharmacokinetics of everolimus and tacrolimus in a heart transplant recipient: Case report.
    Nakagita K, Wada K, Terada Y, Matsuda S, Terakawa N, Oita A, Takada M.
    Int J Clin Pharmacol Ther; 2018 Jun 05; 56(6):270-276. PubMed ID: 29648533
    [Abstract] [Full Text] [Related]

  • 32. Pharmacokinetics of immunosuppressants: a perspective on ethnic differences.
    Dirks NL, Huth B, Yates CR, Meibohm B.
    Int J Clin Pharmacol Ther; 2004 Dec 05; 42(12):701-18. PubMed ID: 15624287
    [Abstract] [Full Text] [Related]

  • 33. Mechanisms of clinically relevant drug interactions associated with tacrolimus.
    Christians U, Jacobsen W, Benet LZ, Lampen A.
    Clin Pharmacokinet; 2002 Dec 05; 41(11):813-51. PubMed ID: 12190331
    [Abstract] [Full Text] [Related]

  • 34. A population pharmacokinetic model of ciclosporin applicable for assisting dose management of kidney transplant recipients.
    Falck P, Midtvedt K, Vân Lê TT, Storehagen L, Holdaas H, Hartmann A, Asberg A.
    Clin Pharmacokinet; 2009 Dec 05; 48(9):615-23. PubMed ID: 19725595
    [Abstract] [Full Text] [Related]

  • 35. Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection.
    Marcén R.
    Drugs; 2009 Nov 12; 69(16):2227-43. PubMed ID: 19852526
    [Abstract] [Full Text] [Related]

  • 36. Moxifloxacin does not alter ciclosporin pharmacokinetics in transplant patients: a multiple-dose, uncontrolled, single-centre study.
    Stass H, Delesen H, Kubitza D, Mai I, Bauer S, Roots I.
    Clin Drug Investig; 2010 Nov 12; 30(5):279-87. PubMed ID: 20384384
    [Abstract] [Full Text] [Related]

  • 37. Immunosuppressive drugs in paediatric liver transplantation.
    van Mourik ID, Kelly DA.
    Paediatr Drugs; 2001 Nov 12; 3(1):43-60. PubMed ID: 11220404
    [Abstract] [Full Text] [Related]

  • 38. Drug interactions with St John's wort : mechanisms and clinical implications.
    Mannel M.
    Drug Saf; 2004 Nov 12; 27(11):773-97. PubMed ID: 15350151
    [Abstract] [Full Text] [Related]

  • 39. Late evolution of kidney transplants in elderly donors and recipients receiving initial immunosuppressant treatment with daclizumab, mycophenolate mofetil, and delayed introduction of tacrolimus.
    González-Roncero FM, Gentil-Govantes MÁ, González-Molina M, Rivero M, Cantarell C, Alarcón A, Franco A, Sánchez-Plumed J, Lampreabe I, Lauzurica R, González E, Romero R, Ruiz-San Millán JC, Osuna A.
    Nefrologia; 2012 Jul 17; 32(4):446-54. PubMed ID: 22806279
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 28.